Hera Biotech
Hera Biotech is a clinical-stage women's health biotech developing AI-powered, non-invasive diagnostics for endometriosis (MetriDx) and cervical cancer (HERAfem), targeting OB-GYN, fertility clinics, primary care, and public health systems across the US, Latin America, Asia, and Africa.
- Company typePrivate
- Founded2022
- HeadquartersSan Antonio, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hera Biotech does
Hera Biotech is a clinical-stage biotechnology company developing non-invasive, tissue-based diagnostics for two under-served areas of women's health: endometriosis and cervical cancer. Its core products are MetriDx, a laboratory-developed molecular test that uses RT-qPCR mRNA expression profiling augmented by AI/ML algorithms to detect and stage endometriosis (reported at 80% sensitivity and 95% specificity), and HERAfem, a point-of-care cervical cancer diagnostic device that combines optical and electrical spectroscopy with on-device AI to detect CIN1+ lesions (reported at 90% sensitivity and 77% specificity). Both products run on a shared adaptive AI platform that improves with each diagnostic result and is trained on 20 billion+ data points across 1,000+ samples and four proprietary datasets.
The company targets OB-GYN clinics, fertility clinics, primary care settings, reference laboratories, and public health systems. Its revenue strategy is multi-modal: MetriDx operates under a Laboratory Developed Test (LDT) model with unique billing opportunities and potential of up to $4M annual revenue per average fertility clinic; HERAfem is positioned as a hardware device sale targeting Latin America (2026), Asia, and Africa (2027). The company is also pursuing reimbursement pathways that could reduce endometriosis diagnostic cost by approximately $17K per patient. Both products remain under development and have not yet received FDA or COFEPRIS approval.
Hera Biotech is a Delaware corporation headquartered in San Antonio, Texas, with regional operations in Monterrey, Mexico and Basel, Switzerland. It is led by CEO Somer Baburek (2 prior exits) and COO/CSO Cinzia Donato, PhD (multi-patent holder, formerly at Scailyte), and is venture-backed with approximately $2M in seed funding plus a $100K Cedars-Sinai Accelerator grant, while actively raising a Series A round for commercialization.
Hera Biotech firmographics
Firmographics- Name
- Hera Biotech
- Legal name
- Hera Biotech, Inc.
- Website
- https://herabiotech.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hera Biotech is a clinical-stage women's health biotech developing AI-powered, non-invasive diagnostics for endometriosis (MetriDx) and cervical cancer (HERAfem), targeting OB-GYN, fertility clinics, primary care, and public health systems across the US, Latin America, Asia, and Africa.
- Ownership category
- akta.pro rank
Hera Biotech industry classification
Industry- Product category
- Women's Health Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Hera Biotech is headquartered
LocationHeadquarters
- HQ city
- San Antonio
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Hera Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- MetriDx™ Diagnostic Testing: Lab-developed test (LDT) model for endometriosis detection, generating revenue through laboratory testing fees prior to FDA approval. Proprietary components and workflow enable unique billing opportunities. Estimated potential of up to $4M annual revenue per average fertility clinic.
- HERAfem™ Device Sales: Point-of-care diagnostic device for cervical cancer screening. Revenue streams planned to turn on pre-COFEPRIS clearance in Latin America (2026) with expansion to Asia and Africa (2027). Device designed for wireless operation with data backup capabilities.
- Reimbursement and Billing: Proprietary diagnostic workflow with unique billing opportunities. MetriDx can cut diagnostic cost by approximately $17K per patient compared to traditional surgical pathway, with reimbursement pathways already in motion.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Hera Biotech product offering
Product offeringCore offering
Hera Biotech develops non-invasive, tissue-based AI-powered diagnostic products for women's health. Its core offerings are MetriDx™, a molecular test using mRNA expression profiling (RT-qPCR) for endometriosis detection and staging (80% sensitivity, 95% specificity), and HERAfem™, a point-of-care cervical cancer diagnostic device using optical and electrical spectroscopy (90% sensitivity, 77% specificity). Both products are powered by a shared adaptive AI/ML platform trained on over 20 billion data points.
Product overview
Hera Biotech offers an AI-powered diagnostic platform with two core products: MetriDx™ for endometriosis detection and staging, and HERAfem™ for cervical cancer diagnosis. Both products share the same AI learning engine but differ in their detection modalities—MetriDx uses molecular mRNA expression profiling via RT-qPCR while HERAfem uses optical and electrical spectroscopy. The platform integrates into existing clinical workflows and improves diagnostic accuracy with each analysis through machine learning.
Differentiator
Problem solved
Functional benefit
Brands
- MetriDx™: Non-invasive molecular test for endometriosis detection and staging using mRNA expression profiling via RT-qPCR with AI-powered algorithms. 80% sensitivity, 95% specificity. Targets to replace surgical diagnostic laparoscopy.
- HERAfem™
Products and services
- MetriDx™ A non-invasive molecular test for endometriosis detection and staging that uses mRNA expression profiling via RT-qPCR enhanced by AI-powered algorithms. Achieves 80% sensitivity and 95% specificity, with results available in 3-5 days via lab processing after Pipelle sampling. Designed for OB-GYN clinics, fertility clinics, primary care, and reference labs to replace surgical diagnostic laparoscopy.
- HERAfem™ A non-invasive, point-of-care cervical cancer diagnostic device that detects CIN1+ lesions using optical and electrical spectroscopy with on-device AI classification. Delivers same-visit results in approximately two minutes without biopsy or lab processing, achieving 90% sensitivity and 77% specificity. Designed for primary care, rural and underserved healthcare environments.
- Hera Biotech Platform An AI-powered diagnostic platform that powers both MetriDx and HERAfem products, collecting biological and physical tissue information and analyzing complexity using adaptive AI/ML models trained on 20 billion+ data points across four proprietary datasets. Designed for frontline care settings including OB-GYN, fertility clinics, and primary care.
Quantifiable outcome
- MetriDx achieves 80% sensitivity and 95% specificity for endometriosis detection
- +5 more outcomes
Companies that use Hera Biotech
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Hera Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Hera Biotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cedars-Sinai AcceleratorcoreSelected for 10th class of Cedars-Sinai Accelerator, receiving $100,000 funding, mentorship, networking, and investor exposure. Culminated in Demo Day at HLTH Event 2024 in Las Vegas.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Hera Biotech competitors and assessment
Company assessmentDirect peers
- DotLab: DotLab develops a blood-based biomarker test for endometriosis, directly competing with Hera's MetriDx in the non-invasive endometriosis diagnostic space and serving a similar OB-GYN and fertility clinic customer base.
- MobileODT (UE LifeSciences): UE LifeSciences (operating the MobileODT cervical screening brand) offers AI-enabled visual cervical cancer screening, directly competing with Hera's HERAfem in point-of-care cervical cancer detection with a similar emerging-market public health focus.
Emerging players
- AOA Dx: AOA Dx is an early-stage women's cancer diagnostics company developing AI-enabled liquid biopsy tests for ovarian cancer, with comparable focus on underserved women's health oncology indications and AI-driven biomarker interpretation.
- Cytovale: Cytovale develops AI-enabled rapid diagnostics (notably IntelliSep for sepsis), sharing Hera's AI-powered platform approach to non-invasive diagnostics with similar point-of-care deployment ambitions and machine learning interpretation engines.
- TruDiagnostic: TruDiagnostic uses AI/ML on multi-omics data (epigenetic and methylation biomarkers) for health diagnostics, overlapping with Hera's bioinformatics and multi-omics data infrastructure in the broader AI diagnostics category.
- iCAD: iCAD applies AI to cancer detection and therapy planning (notably breast and cervical), sharing Hera's AI-imaging-and-biomarker diagnostic approach for women's cancers with an established commercial footprint.
Broad incumbents
- Hologic: Hologic is a global women's health diagnostics leader with strong cervical cancer screening (ThinPrep, Genius) and molecular diagnostics franchises, representing a likely strategic acquirer or major competitor for Hera's HERAfem and MetriDx products.
- QIAGEN: QIAGEN is a leading molecular diagnostics and sample-preparation company with broad RT-qPCR workflows that overlap with MetriDx's laboratory-based molecular diagnostic methodology and could serve as a reference lab distribution partner.
- Becton Dickinson (BD): BD is a major diagnostics and medical device incumbent with women's health and molecular diagnostic franchises, overlapping with Hera's combined diagnostics-device offering and serving as a likely strategic partner or acquirer.
- F. Hoffmann-La Roche: Roche Diagnostics is the global leader in molecular diagnostics and women's health (including HPV primary screening via cobas), representing both a competitive threat and a likely strategic acquirer for an AI-enabled endometriosis and cervical cancer diagnostic platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights1 record
Customer concentration
Hera Biotech social profiles
Digital presenceHera Biotech compliance and trust
Trust signalCompliance3 records
Hera Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hera Biotech leadership team
Management profileNumber of profiles
Profiles10 records
Hera Biotech subsidiaries and ownership
Company hierarchySubsidiaries1 record
Hera Biotech funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hera Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hera Biotech
What does Hera Biotech do?
Hera Biotech develops non-invasive, tissue-based AI-powered diagnostic products for women's health. Its core offerings are MetriDx™, a molecular test using mRNA expression profiling (RT-qPCR) for endometriosis detection and staging (80% sensitivity, 95% specificity), and HERAfem™, a point-of-care cervical cancer diagnostic device using optical and electrical spectroscopy (90% sensitivity, 77% specificity). Both products are powered by a shared adaptive AI/ML platform trained on over 20 billion data points.
Is Hera Biotech a public or private company?
Hera Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hera Biotech founded?
Hera Biotech was founded in 2022. It employs 1 to 10 people.
Where is Hera Biotech based?
Hera Biotech is headquartered in San Antonio, United States, in the North America region.
How does Hera Biotech make money?
Three revenue lines are on record. MetriDx™ Diagnostic Testing is the primary driver. The others are HERAfem™ Device Sales and reimbursement and Billing.
Who are Hera Biotech's main competitors?
Direct peers on record are DotLab and MobileODT (UE LifeSciences). Emerging players are AOA Dx, Cytovale, TruDiagnostic and iCAD. Broad incumbents are Hologic, QIAGEN, Becton Dickinson (BD) and F. Hoffmann-La Roche.
Does Hera Biotech have an API?
No public API is recorded for Hera Biotech.
What industry is Hera Biotech in?
Hera Biotech's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 325413 and its SIC code is 2835.